Thalys Medical Technology Group (SHSE:603716) COGS-to-Revenue : 0.76 (As of Mar. 2025)

View and export this data going back to 2016. Start your Free Trial

What is Thalys Medical Technology Group COGS-to-Revenue?

Thalys Medical Technology Group's Cost of Goods Sold for the three months ended in Mar. 2025 was ¥220 Mil. Its Revenue for the three months ended in Mar. 2025 was ¥287 Mil.

Thalys Medical Technology Group's COGS to Revenue for the three months ended in Mar. 2025 was 0.76.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Thalys Medical Technology Group's Gross Margin % for the three months ended in Mar. 2025 was 23.60%.

Thalys Medical Technology Group COGS-to-Revenue Historical Data

The historical data trend for Thalys Medical Technology Group's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Thalys Medical Technology Group COGS-to-Revenue Chart

Thalys Medical Technology Group Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

COGS-to-Revenue

Get a 7-Day Free Trial

0.77

0.79

0.80

0.82

Thalys Medical Technology Group Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
COGS-to-Revenue	Get a 7-Day Free Trial															0.77	0.85	0.78	0.87	0.76

Thalys Medical Technology Group COGS-to-Revenue Calculation

Thalys Medical Technology Group's COGS to Revenue for the fiscal year that ended in Dec. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	1478.799	/	1810.681
	=	0.82

Thalys Medical Technology Group's COGS to Revenue for the quarter that ended in Mar. 2025 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	219.586	/	287.429
	=	0.76

Thalys Medical Technology Group (SHSE:603716) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Thalys Medical Technology Group's Gross Margin % for the three months ended in Mar. 2025 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	219.586 / 287.429
	=	23.60 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Thalys Medical Technology Group COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Thalys Medical Technology Group's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Thalys Medical Technology Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Thalys Medical Technology Group Corp (SHSE:603716) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

1310 Jinshan Avenue, Dongxihu District, Hubei Province, Wuhan, CHN, 430040

Website

https://www.thalys.net.cn

Thalys Medical Technology Group Corp is engaged in intensive sales business, pure sales, and research and development, production and sales of independent in vitro diagnostic products.

Executives

Wang Jun Ming	senior management
Wang Zheng	senior management
Wang Wen Bin	senior management
Liu Wen Hao	Director
Huang Yong Xi	senior management
Lei Xian Kun	Director
Fan Li	Director
Liu Yuan	senior management
Wan Li Bo	senior management
Wen Wei	Director
Chou Jian	senior management
Song Yu	Director

Thalys Medical Technology Group Headlines

No Headlines